2026-07-21T15:51:37Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/65462024-11-29T17:58:15Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc de Carcer Diez, Guillermo author Venkateswaran, Sharavan Vishaan author Salgueiro, Lorena author El Bakkali, Aicha author Somogyi, Kalman author Rowald, Konstantina author Montañés, Pablo author Sanclemente, Manuel author Escobar, Beatriz author de Martino, Alba author McGranahan, Nicholas author Malumbres Martinez, Marcos author Sotillo, Rocío author 2018-08-01 Polo-like kinase 1 (Plk1) is overexpressed in a wide spectrum of human tumors, being frequently considered as an oncogene and an attractive cancer target. However, its contribution to tumor development is unclear. Using a new inducible knock-in mouse model we report here that Plk1 overexpression results in abnormal chromosome segregation and cytokinesis, generating polyploid cells with reduced proliferative potential. Mechanistically, these cytokinesis defects correlate with defective loading of Cep55 and ESCRT complexes to the abscission bridge, in a Plk1 kinase-dependent manner. In vivo, Plk1 overexpression prevents the development of Kras-induced and Her2-induced mammary gland tumors, in the presence of increased rates of chromosome instability. In patients, Plk1 overexpression correlates with improved survival in specific breast cancer subtypes. Therefore, despite the therapeutic benefits of inhibiting Plk1 due to its essential role in tumor cell cycles, Plk1 overexpression has tumor-suppressive properties by perturbing mitotic progression and cytokinesis. Nat Commun. 2018; 9(1): 3012. 10.1038/s41467-018-05429-5 2041-1723 2041-1723 Nature communications 30069007 http://hdl.handle.net/20.500.12105/6546 POLO-LIKE KINASE BREAST-CANCER THERAPEUTIC TARGETS ANTICANCER THERAPY MAMMALIAN-CELLS ESCRT MACHINERY SCREEN ANEUPLOIDY EXPRESSION MICE Plk1 overexpression induces chromosomal instability and suppresses tumor development